| Sonstiges: |
- Nachgewiesen in: USPTO Patent Applications
- Sprachen: English
- Document Number: 20090098583
- Publication Date: April 16, 2009
- Appl. No: 11/627784
- Application Filed: January 26, 2007
- Claim: 1-40. (canceled)
- Claim: 41. A method to detect early renal disease comprising: (a) obtaining a sample from an animal; and (b) determining the amount of albumin in said sample, wherein an amount of albumin in a range from about 10 μg/ml to about 300 μg/ml in the sample, when the specific gravity of the sample is normalized to 1.010 g/ml, is indicative of early renal disease.
- Claim: 42. The method of claim 41, wherein the method is repeated at least once to monitor a disease or the effect of a therapy.
- Claim: 43. The method of claim 41, wherein the amount of albumin in the sample is determined by: (a) contacting the sample with an albumin-binding compound to form an albumin-compound complex; (b) detecting the albumin-compound complex; and (c) assessing the amount of albumin present in the sample from the amount of albumin-compound complex detected.
- Claim: 44. The method of claim 43, wherein the albumin-binding compound is an anti-albumin antibody.
- Claim: 45. The method of claim 44, wherein said antibody inhibits the selective binding of a test antibody selected from the group consisting of H352, H386, H387, H388, H389, H390, H391, H393, H394, H395, H396, H397, H398, H399, H400, H401 and H402 to albumin.
- Claim: 46. The method of claim 44, wherein the antibody binds the same epitope recognized by a test antibody selected from the group consisting of H352, H386, H387, H388, H389, H390, H391, H393, H394, H395, H396, H397, H398, H399, H400, H401 and H402.
- Claim: 47. The method of claim 41, wherein the amount of albumin in the sample is determined using an assay selected from the group consisting of an enzyme-linked immunoassay, a radioimmunoassay, a fluorescence immunoassay, a chemiluminescent assay, a lateral-flow assay, a dipstick assay, an agglutination assay, a particulate-based assay, an immunoprecipitation assay, an immunodot assay, an immunoblot assay, an immunodiffusion assay, a phosphorescence assay, a flow-through assay, a chromatography assay, a PAGe-based assay, an electronic-sensory assay, a surface plasmon resonance assay and a fluorescence correlation spectroscopy assay.
- Claim: 48. The method of claim 41, wherein the animal is selected from the group consisting of canids, felids and equids.
- Claim: 49. The method of claim 41, wherein the sample is pre-treated by adjusting the specific gravity to 1.010 g/ml.
- Claim: 50. A kit comprising a means for detecting early renal disease according to the method of claim 41.
- Claim: 51. A method to identify an animal at risk for developing late-stage renal disease comprising: (a) obtaining a sample from the animal; and (b) determining the amount of albumin in said sample, wherein an amount of albumin in a range from about 10 μg/ml to about 300 μg/ml in the sample, when the specific gravity of the sample is normalized to 1.010, indicates the animal is at risk for late-stage renal disease.
- Claim: 52. The method of claim 51, wherein the animal is selected from the group consisting of canids, felids and equids.
- Claim: 53. The method of claim 51, wherein the amount of albumin in the sample is determined by: (a) contacting the sample with an albumin-binding compound to form an albumin-compound complex; (b) detecting the albumin-compound complex; and (c) assessing the amount of albumin present in the sample from the amount of albumin-compound complex detected.
- Claim: 54. The method of claim 53, wherein the albumin-binding compound is an anti-albumin antibody.
- Claim: 55-60. (canceled)
- Claim: 61. A device for detecting early renal disease in an animal, said device comprising: (a) a support structure defining a flow path; (b) a labeling reagent comprising a detectable marker conjugated to an albumin-binding compound, the labeling reagent being impregnated within the support structure in a labeling zone, wherein said albumin-binding compound selectively binds to animal albumin; and (c) a capture reagent being present in a capture zone, said capture zone being fluidly connected to the labeling zone.
- Claim: 62. The device of claim 42, wherein said device detects albumin in a sample from said animal when the amount of albumin present in the sample is in a range from about 10 μg/ml to about 300 μg/ml when the specific gravity of the sample is normalized to 1.010 g/ml.
- Claim: 63. The device of claim 42, wherein said device detects albumin when the albumin in the sample is in a range from about 10 μg/ml to about 50 μg/ml when the specific gravity of the sample is normalized to 1.010 g/ml.
- Claim: 64. The device of claim 42, wherein the albumin-binding compound is an antibody.
- Claim: 65. The device of claim 42, wherein said capture reagent is an anti-albumin antibody.
- Claim: 66. The device of claim 42, wherein said detectable marker is a bead.
- Current U.S. Class: 435/792
- Current International Class: 01; 01; 01; 12; 01
|
